PRME - NASDAQ

Prime Medicine, Inc.

PRME·NASDAQ

$3.14

-2.2%

HealthcareBiotechnology

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$567.14M

EPS-1.3500

P/E Ratio-2.33

Earnings Date08/06/2026

prme

Total Non-Current Assets

Last Annual Value

161.44M

3-Year CAGR

36%

5-Year CAGR

159%

10-Year CAGR

Adjust for Inflation

Prime Medicine, Inc. Competitors Analysis of Total Non-Current Assets

PRME · NASDAQ

Company	Total Non-Current Assets	CAGR 3Y	CAGR 5Y	CAGR 10Y
Prime Medicine, Inc. NASDAQ:PRME	161.44M	46.9%	38.9%	N/A
ProKidney Corp. NASDAQ:PROK	54.90M	5.8%	33.3%	N/A
Kura Oncology, Inc. NASDAQ:KURA	29.70M	21.8%	20.4%	40.2%
Septerna, Inc. NASDAQ:SEPN	185.22M	116.8%	N/A	N/A
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT	35.34M	50.4%	6.6%	35.8%
Replimune Group, Inc. NASDAQ:REPL	55.45M	0.9%	-1.4%	N/A
Rezolute, Inc. NASDAQ:RZLT	4.34M	-38.6%	47.8%	-3.8%
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI	474.33M	-15.5%	-16.6%	N/A
Tyra Biosciences, Inc. NASDAQ:TYRA	17.16M	6.5%	45.4%	N/A
Vir Biotechnology, Inc. NASDAQ:VIR	488.74M	13.9%	4.5%	N/A
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	8.94M	45.4%	N/A	N/A

Prime Medicine, Inc. Fair Value Envelope

PRME · NASDAQ

Our analysis suggests that PRME has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.14, this represents a potential HIDDEN relative to our calculated worth for Prime Medicine, Inc..

HIDDEN

Intrinsic Value

Current Price: $3.14

Related Guides

Blog Categories

Continue your PRME research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.